Eikon reports updated EIK1001 lung cancer trial results at ESMO
Eikon Therapeutics presented updated TeLuRide-005 results for EIK1001 combined with pembrolizumab and chemotherapy at the ESMO 2026 Congress on October 26, 2026. Across 65 efficacy-evaluable NSCLC patients, the combination produced a 63.1% ORR and 89.2% DCR; the squamous subgroup recorded a 72.4% ORR, 100% DCR and 12.9-month median response duration. Eikon is enrolling the Phase 2/3 TeLuRide-008 study and anticipates a dose-selection interim analysis in 2H 2027.
Why it matters
The results add clinical data supporting Eikon's continued development of EIK1001 in advanced NSCLC, while the next specified development milestone is the TeLuRide-008 interim analysis. The reported safety profile and ongoing enrollment change the timing of the next material readout for investors, but the materials do not establish comparative efficacy against standard treatment.
Key facts
- 1The TeLuRide-005 efficacy population comprised 65 patients, with 63.1% ORR and 89.2% DCR across the NSCLC cohorts. tradingview.com
- 2The squamous subgroup had a 72.4% ORR, 100% DCR and 12.9-month median duration of response. investing.com
- 3Grade 3 or higher treatment-related adverse events occurred in 48.6% of the 72 safety-evaluable participants. investing.com
- 4Eikon expects the TeLuRide-008 dose-selection interim analysis in 2H 2027. stocktitan.net
- 5The non-squamous subgroup showed a 55.6% ORR and 80.6% DCR, with an 11.2-month median duration of response. investing.com
Open questions
- places the Phase 2/3 interim analysis in late 2027, while specify 2H 2027.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.